Dental Practice Valuation & EBITDA Multiples
Dental practices sell for 5x–11x adjusted EBITDA in 2026, with PE-backed DSO platforms paying 9–11x for regional groups and 10–12x+ for $5M+ EBITDA platform-grade practices. Hygiene revenue above 30% and associate-led production are the two highest-leverage value drivers.
Updated 2026-06-05·14 min read·Healthcare Services & IT
Adjusted EBITDA multiple
5x – 11x
Typical: 7.5x · Sample: Triangulated from FOCUS Investment Banking 2026 ranges, Sorso 2026, Large Practice Sales 2024 results (6.75x–11.25x), PitchBook Q2–Q3 2025 Healthcare Services, and named DSO transactions Q3 2025 – Q2 2026
- Adj. EBITDA range
- 5x – 11x
- Dominant buyer type above $5M EBITDA
- PE-backed DSOs
- Expect higher 2026 acquisition volume
- 61% of DSOs
- Typical cash at close (15–30% mandatory rollover)
- 60–75%
Quick answer
A dental practice typically sells for 5x–11x adjusted EBITDA, depending on size and structure [1][2]. Single-doctor and add-on practices cluster at 5–8x EBITDA; $1–3M EBITDA associate-led groups clear 7–9x; emerging multi-location platforms ($3–5M EBITDA) reach 9–11x; and $5M+ EBITDA platform-grade DSO groups reach 10–12x+. Large Practice Sales reported 2024 outcomes ranging from 6.75x to 11.25x EBITDA (up to 375% of collections), confirming the platform/add-on spread is real and earned [10]. Deal velocity is accelerating: 61% of surveyed DSOs report PE backers expect moderate-to-high increases in 2026 acquisition activity [8][7].
The two highest-leverage value drivers are hygiene revenue above 30% of collections — tied to premium multiples and better DSO offers [1] — and owner-doctor production share below 70%. Per Sofer Advisors (cited via FOCUS), practices where the owner performs 90%+ of production face a 10–20% valuation reduction [9][1]. The dominant buyer pool is PE-backed DSOs: Heartland Dental (KKR), Aspen Dental / TAG (Leonard Green), Smile Brands (Gryphon), Sage Dental, CORDENTAL (NMS Capital), and specialty consolidators. Deals close 60–75% cash at close, with 15–30% rollover equity effectively mandatory in DSO structures [1][2].
Multiples by size
How dental practice multiples shift with EBITDA size
The single biggest determinant of multiple is size. The same business at 4x sub-$1M EBITDA can fetch 7x once it crosses $5M — same operations, different buyer pool.
| Adjusted EBITDA range | Multiple range | What's typical here |
|---|---|---|
| Under $500K Adj. EBITDA | 3x – 5x | Solo owner-producer practice. Buyer pool is individual dentists with SBA financing. DSOs rarely engage below $250K post-doctor-comp EBITDA; practices below $1.5M collections typically sell doctor-to-doctor at 50–100% of collections. |
| $500K – $1M Adj. EBITDA | 5x – 7x | The SDE-to-EBITDA transition zone. DSO add-on candidates in established metros. Hygiene mix and associate coverage begin moving the multiple. Structure shifts toward 70–80% cash with 10–20% rollover and a modest earn-out. |
| $1M – $3M Adj. EBITDA | 7x – 9x | The most competitive band. Both DSO add-on and emerging-platform buyers submit LOIs. Associate-led production with owner below 70% of chair time drives the upper end; multi-location clusters of 2–4 offices start commanding emerging-platform pricing. |
| $3M – $5M+ Adj. EBITDA | 9x – 11x | Platform-grade regional groups, often with specialty mix (ortho, OMS, perio). PE platform recap candidates. Specialty premiums layer on: ortho 7–10x, OMS 6–9x as add-ons; specialty platforms 12x+. Structure typically 60% cash / 30% rollover / 10% holdback. |
Interactive estimate
Estimate the range for your business
Move the sliders. The estimate reflects how each driver pushes the multiple up or down inside the bands above. Use this as a planning anchor — not a sale price.
Recurring hygiene visits signal a stable, transferable patient base. Sources tie hygiene above 28–33% of collections to premium multiples and better DSO offers; the precise numeric turn-premium is directional.
The single highest-leverage de-risking variable. Sofer Advisors (cited via FOCUS) quantifies a 10–20% valuation reduction for owner-doctor 90%+ production practices. Provider risk became a primary decision driver in 2026 per TUSK Q1 2026.
Platform deals trade 9–11x EBITDA vs add-ons at 5–8x. Three or more offices with shared management infrastructure anchors emerging-platform pricing; single-location practices cap at the add-on band.
Commercial/PPO strength signals less reimbursement volatility. Heavy Medicaid/HMO concentration is now a state-level underwriting variable per TUSK Q1 2026 and can compress the multiple 0.5–1.0x.
Estimated enterprise value
$7.5M – $13.5M
Implied multiple: 5.0x – 9.0x Adjusted EBITDA
This is a planning estimate, not a formal valuation. Real-world ranges are narrowed by adjusted EBITDA quality, payer mix, DSO compatibility, payor credentialing timelines, and the negotiated deal structure. Ad Astra delivers advisor-grade ranges under USPAP/SSVS standards.
Value drivers
What moves the multiple, specific to dental practice
Hygiene revenue >30% of collections
+0.5x – 1.0xRecurring hygiene visits are the strongest signal of a stable, transferable patient base. DSO buyers underwrite forward cash flow on the assumption that a hygiene-dense schedule will survive the selling dentist's exit. Sources tie hygiene above 28–33% of collections to premium multiples and better DSO offers [1]. Track hygiene reappointment rate, 6-month recall compliance, and the hygiene-to-restorative conversion rate — buyers will ask for all three in diligence.
Note: the precise numeric multiple turn for crossing the 30% threshold is directional [1][2] — use the +0.5x–1.0x range as a planning estimate, not a guarantee.
Associate-led production (owner <70% of chair time)
+0.5x – 1.5xThis is the single highest-leverage de-risking variable in dental M&A. When the owner produces less than 60–70% of clinical revenue, the DSO can underwrite future cash flow without you — key-person risk falls, and the earnout clause shrinks. Per Sofer Advisors (cited via FOCUS), practices where the owner performs 90%+ of production face a 10–20% valuation reduction [9][1]. TUSK Q1 2026 confirmed provider risk moved from a background consideration to a primary decision driver for DSO acquirers in 2026 [7].
The path: hire a full-time associate at least 18–24 months before a planned sale, document their production trend, and step back from a majority of chair time incrementally.
Multi-location regional cluster (3–10 offices)
+2x – 4x platform premiumThe biggest scale-driven lift in dental is the jump from add-on to platform pricing. Platform deals trade at 9–11x EBITDA vs add-ons at 5–8x [1] — a spread of 2–4 turns on the same underlying EBITDA. Emerging-platform pricing starts at approximately the third location once shared management infrastructure (office manager, billing team, credentialing staff) is in place. A 7-location regional group with ortho mix in the same metro can clear 9.5x, as illustrated in the comps below.
Single-location practices, regardless of EBITDA quality, are capped at add-on multiples in most DSO models.
EBITDA scale $1M – $5M+
+1x – 2xLarger absolute EBITDA generates competitive tension: at $1M+ EBITDA, a well-positioned practice can attract 3–5 letters of intent simultaneously, allowing the seller's advisor to run a true auction. $1M+ EBITDA practices attract both financial (DSO add-on) and strategic (platform recap) buyers, driving the multiple toward the upper end of the applicable size band [5][10]. GF Data confirms the LMM size premium widened to 2.8x EBITDA in the first nine months of 2025 — larger and cleaner beats merely better [11].
Diversified PPO/FFS payer mix (commercial-heavy)
+0.5xA commercial/PPO-heavy mix signals lower reimbursement volatility and supports premium pricing. Fee-for-service collections carry the highest per-procedure yield and the clearest transfer to an incoming operator. Payer mix has become a state-level underwriting variable in 2026 — DSO acquirers are now scrutinizing state Medicaid policy alongside practice financials when underwriting deals [7]. Commercial-heavy practices avoid this additional diligence friction, supporting faster close timelines and higher cash-at-close allocations.
Single owner-doctor producing 90%+ of revenue
-10% to -20% of valuePer Sofer Advisors (cited via FOCUS Investment Banking), practices where the owner performs 90%+ of production may experience valuation reductions of approximately 10–20% [9][1]. The mechanism is simple: a DSO cannot underwrite the production revenue that walks out the door with the seller. Buyers typically respond with a lower headline multiple, a larger earnout tied to retained EBITDA, and/or a longer transition employment requirement. This is the most common and most preventable discount in dental M&A.
Sub-$500K EBITDA / solo practice
Caps at ~3x – 4x EBITDABelow approximately $500K adjusted EBITDA, the buyer pool collapses to individual dentists and SBA-financed buyers. DSO/IDSO platforms typically do not engage below $250K post-doctor-comp EBITDA [10] and rarely run competitive processes for practices under $1.5M in collections. Without multiple bidders, there is no auction — and without an auction, there is no platform multiple. The structure also shifts: 80–90% cash with a seller note is common, and no rollover equity means no second-bite upside.
Heavy Medicaid/HMO payer concentration
-0.5x – 1.0xState Medicaid policy is now a state-level underwriting variable for DSO acquirers [7]. Practices with 40%+ of collections from Medicaid or HMO plans face multiple compression of 0.5–1.0x as buyers model the reimbursement rate risk, managed-care re-credentialing complexity, and potential for state policy changes post-close. The discount is especially pronounced in states with contested Medicaid dental benefit legislation. Commercial/PPO-heavy practices do not carry this risk premium.
Deferred technology capex (no CBCT, aging chairs, paper-based ops)
-0.25x – 0.5xDSO acquirers normalize the post-close equipment upgrade bill against purchase price. Aging operatories without cone-beam CT (CBCT), no digital impressions, paper charts, and outdated sterilization equipment signal a $100K–$500K upgrade cost that comes directly out of the enterprise value in buyer models [2]. A CBCT, CAD-CAM, and fully digital workflow remove this discount — and in specialty practices (ortho, OMS) up-to-date imaging technology is effectively non-negotiable for top-quartile multiples.
Buyer landscape
Who is actively buying dental practice
Named PE platforms, strategic acquirers, and consolidators active in the space in the last 12 months. Multiples paid by these buyers anchor the high end of our range.
Heartland Dental
Backed by KKR
The largest US DSO by location count, Heartland buys multi-location practices into a supported-autonomy operating model and pays platform multiples for clean regional clusters in underserved geographies.
- Closed acquisition of Smile Design Dentistry (60 Florida practices, sold by Tenex Capital) on Sept 5, 2025
- 3,000+ affiliated doctors across 1,800+ locations in 39 states
Aspen Dental / TAG – The Aspen Group
Backed by Leonard Green & Partners
Retail-oriented affiliated DSO model with a strong consumer brand; pursues de novo expansion alongside acquisitions and is especially active in underserved markets and Medicaid-accessible demographics.
- Recently opened new affiliated offices in Georgia and New Jersey
- One of the largest US DSOs by patient volume across the Aspen Dental, WellNow Urgent Care, and ClearChoice brands
Smile Brands
Backed by Gryphon Investors
Multi-brand DSO operating Bright Now! Dental, Castle Dental, Monarch Dental, and others; acquires regional single-brand groups and integrates them under the multi-brand umbrella.
- Acquired Midwest Dental (multi-location group) in 2025
Sage Dental
Boca Raton-based DSO focused on the Southeast US; targets single-location and small-group add-ons within existing cluster markets to build density before a platform recap.
- Acquired Kendall Dental Care (Miami, FL) in 2025
CORDENTAL Group
Backed by NMS Capital
Mid-Atlantic and Midwest add-on consolidator focused on practice partnerships that retain doctor autonomy within a shared-services infrastructure.
- Partnered with Williamsburg Dental (Broomall, PA) in 2025
MB2 Dental
Doctor-owned DSO with a partnership-equity model popular as an IDSO option for owner-dentists who want to retain meaningful operational control plus a second-bite equity upside on the platform's eventual recap.
- Active partnership program across multiple states; specific 2025 transaction details were not surfaced in the current research set — the platform thesis is well-documented and the buyer is named in the research files
Pacific Dental Services
One of the largest US DSOs by office count; supported-affiliation model with a focus on de novo growth alongside acquisitions, strong in the Southwest and Pacific Coast markets.
- Continued de novo and acquisition expansion; specific 2025 named transaction not surfaced in the current research set
Park Dental Partners
Scaled DSO accessing public markets; 85+ affiliated practices across Minnesota and Wisconsin, pursuing growth through affiliated-practice expansion in the Upper Midwest.
- IPO on Nasdaq (PARK) in December 2025: 1,535,000 shares at $13.00 per share (~$20M gross proceeds)
Deal structure
Headline price is one number. The structure is the deal.
Headline price gets the press release. In DSO transactions, rollover equity is effectively mandatory — typically 15–30% of total consideration taken as JV equity in the doctor's home practice, holdco equity in the parent DSO, or a hybrid structure [1][2]. The seller is underwriting the platform's next exit alongside the sponsor, and the "second-bite" upside is the central economic incentive in every DSO partnership conversation. Recent platform deals include Heartland Dental's (KKR) acquisition of Smile Design Dentistry (60 Florida practices) closed Sept 5, 2025 [3] and Park Dental Partners' Nasdaq IPO in December 2025 [12].
Below is the typical breakdown for dental platform and add-on deals in the $500K–$5M+ EBITDA range, 2024–2026. Platform deals ($3M+ EBITDA) tilt toward the upper end of cash at close; add-ons below $1M EBITDA carry heavier rollover and earn-out. Dental transactions run 6–12 months engagement-to-close due to payor credentialing and state CON requirements [2].
Typical breakdown
- Cash at close
- 60–75%
- Rollover equity
- 15–30%
- Earn-out
- 5–15%
- Seller note
- 0–5%
- Working capital adjustment
- ±2–3%
Senior debt plus PE sponsor equity. Tilts toward 70–75% for $3M+ EBITDA platform deals, toward 60–65% for add-ons with heavier rollover components.
Effectively mandatory in DSO structures. Taken as JV equity, holdco equity, or a hybrid. Hold period is typically 3–7 years to the next sponsor recapitalization.
Tied to retained EBITDA over 12–36 months. Used to bridge valuation gaps where associate retention or payer-mix transition risk needs to be priced in at close.
Uncommon in DSO structures (data on seller-note frequency in DSO deals is limited); occasionally used in sub-$1M EBITDA add-ons where SBA-style buyers also participate.
True-up at closing against a negotiated working capital peg. Pre-negotiate the peg before the LOI is signed to avoid post-close drag on the net proceeds.
Recent comps (anonymized)
Representative dental practice transactions
| Profile | Closed | Multiple | Buyer | Structure |
|---|---|---|---|---|
| $1.1M collections / $230K EBITDA solo GP, owner produces 92% of revenue, rural Midwest. Illustrative model based on published ranges (FOCUS, Jaffe Law). | 2025 Q2 | 4.0x | Individual / SBA buyer | 90% cash / 10% seller note |
| $2.4M collections / $480K EBITDA, 2 operatories, hygiene 34% of collections, suburban Mountain West. Illustrative model based on published ranges (FOCUS 5–8x add-on). | 2025 Q1 | 6.5x | DSO add-on | 75% cash / 15% rollover / 10% earn-out |
| $5.5M collections / $1.2M EBITDA, 4 locations, associate-led, Southeast. Illustrative model based on published ranges (McLerran 7–9x for $1M+ EBITDA). | 2024 Q4 | 8.0x | DSO add-on / emerging platform | 70% cash / 20% rollover / 10% earn-out |
| $12M collections / $2.6M EBITDA, 7-location regional platform, ortho mix. Illustrative model based on published ranges (FOCUS 9–11x platform). | 2025 Q2 | 9.5x | PE platform recap | 60% cash / 30% rollover / 10% holdback |
| MAX Surgical Specialty Management — multi-location OMS group, Northeast. Real financing event. | 2025 | n/a (financing) | Specialty OMS DSO — senior debt facility | $77M senior credit facility |
| Smile Design Dentistry — 60 affiliated dental practices in Florida, sold by Tenex Capital to Heartland Dental (KKR). Real platform-to-platform transaction. | Sept 5, 2025 | Undisclosed | Heartland Dental (KKR-backed PE platform) | Undisclosed |
| Park Dental Partners — 85+ affiliated practices in MN/WI. Real public-markets event. | Dec 2025 | IPO: 1,535,000 shares @ $13.00 (~$20M gross) | Public markets (Nasdaq: PARK) | IPO |
Profiles aggregated from public PE press releases and internal Ad Astra advisory data. Cited where attribution is public.
Methodology
How valuation methods apply to dental practice
Comparable transactions — the anchor for dental
For dental practices, the comparable-transactions method is the strongest anchor because the comp set is unusually rich. FOCUS Investment Banking, Sorso, McLerran, Large Practice Sales, and PrivSource have publicly tracked DSO add-on and platform deals for years, creating one of the deepest private healthcare-services M&A databases in the lower middle market [1][2][5][4]. Group Dentistry Now's 2025 deal roundup captures real transactions including the SF Dental Group 5-location California platform launch [6] and the Park Dental Partners IPO [12].
Build the comp set on two axes: size band (sub-$500K EBITDA vs $1–3M vs $3M+ are structurally different buyer pools and price ranges) and practice type (general vs specialty — ortho, perio, OMS, and endo each carry distinct premiums per Sorso 2026 [2]). Specialty platforms reach 12x+ where add-on specialty practices stay in the 6–10x range. PE-backed DSO platforms close most transactions above $5M EBITDA per PitchBook [1].
Note: Jaffe Law's more conservative 5–7x platform / 2–4x add-on framing reflects a looser definition of platform. This page leads with FOCUS's 9–11x platform / 5–8x add-on framing, which matches DSO market reality for practices with $1M+ EBITDA and associate-led production [1].
Discounted cash flow — the normalization test for doctor comp
DCF is useful in dental as a check on doctor-compensation normalization and as a way to value the recurring hygiene stream separately from production. The key add-back in dental is owner-doctor production compensation normalized to a market clinical rate (typically 28–32% of production for a GP) — this adjustment often produces $80K–$300K in normalized EBITDA uplift for solo-producer practices and is the most contested add-back in QoE [1].
Run a 5-year forecast with explicit modeling of: (a) hygiene-to-restorative conversion rate, (b) new-patient flow by channel, (c) PPO write-offs by carrier, and (d) associate compensation at market collection rate. Terminal value should anchor to a market exit multiple in the applicable size band [2], not a perpetual-growth assumption. DSO buyers frequently run their own DCF as a counter-model to the seller's EBITDA-multiple ask.
Asset-based — the floor check and goodwill allocation
For a healthy dental practice, asset value (chairs, CBCT, CAD-CAM, lab equipment, leasehold improvements, working capital, and patient list intangibles) typically lands well below operating value. Use it as a sanity check: if asset value is within 30% of operating value, EBITDA quality is likely overstated or the normalization is incomplete.
76%+ of the purchase price typically flows to goodwill for tax-allocation purposes [10] — a key seller-side benefit, as goodwill is taxed at long-term capital gains (20% + 3.8% NIIT = 23.8% federal) rather than ordinary income rates that apply to equipment recapture and non-compete payments. The allocation is negotiated at LOI and is material — model your after-tax proceeds before signing. For comparison: non-compete and employment-agreement payments are ordinary income; equipment recapture is taxed at ordinary rates up to the original cost basis.
Sell-side adjustments
The adjustments that protect — and grow — your reported EBITDA
Each item below is something we expect to debate with a buyer's QoE provider. Document them yourself, with backup, before going to market.
Owner-doctor production compensation normalized to market clinical rate
+$80K – $300KOwner-doctors frequently pay themselves at production rates that distort reported EBITDA. DSO buyers normalize to a market clinical rate (typically 28–32% of production for a GP, higher for specialty). For solo-producer practices this is usually an upward EBITDA adjustment; for owners over-paying themselves it runs downward. Document with a state and specialty benchmark.
Family members on payroll at above-market rates
+$30K – $150KSpouse as office manager at $90K when the market rate is $55K; adult children with W-2s and no substantive role. Strip the delta with job descriptions and documented market compensation. Buyers will scrutinize every W-2 in diligence.
Owner-occupied building rent (above or below market)
+/- $25K – $120KIf the owner owns the real estate and charges the practice below-market rent, the buyer adjusts EBITDA upward to reflect a market lease rate (real estate is purchased separately or leased at arm's-length). If rent is above market, a downward adjustment applies. Negotiate the real estate disposition separately from the practice enterprise value.
Deferred technology and equipment capex
-$50K – $300KAging operatories, no CBCT, paper charts, no CAD-CAM or digital impressions, and outdated sterilization — the buyer normalizes the post-close upgrade cost (often $100K–$500K) against purchase price. A modern, fully digital workflow removes this deduction from the enterprise value. This is a negative adjustment to EV, not EBITDA.
Personal vehicle, club memberships, travel, professional dues
+$15K – $80KCountry club, gym, family vacations booked as CE travel, and personal vehicles run through the P&L. Strip out with contemporaneous documentation. ADA-compliant CE travel stays; personal lifestyle expenses go. Buyers will request 36 months of credit card statements in QoE.
One-time and non-recurring items
Varies — case by casePPP forgiveness (still appearing on 2021–2022 P&Ls in some practices), COVID-era PPE buys, one-time legal settlements, and PMS/EHR implementation costs. Each normalized out of the base-year EBITDA. Normalize across all three years and present a consistent adjusted EBITDA bridge.
Associate-doctor production guarantees being normalized
+$25K – $150KWhere the practice paid an associate a base salary guarantee above their actual production during a ramp-up period, normalize to production-based compensation at market collection rate. Buyers want to see recurring associate economics, not the transition subsidy — a still-ramping associate can look like an EBITDA drag without this adjustment.
FAQ
Common questions about dental practice valuation
Dental Practice vs comparable industries
Ready to actually sell?
Get an owner-grade range for your dental practice
A confidential 30-minute call with Clayton or Joe gives you a real range, the adjustments we'd apply to your reported EBITDA, and the one or two moves that close the gap fastest.
- [1] FOCUS Investment Banking — Dental Practice EBITDA Multiples 2026
- [2] Sorso — Dental Practice EBITDA Multiple 2026
- [3] Heartland Dental — Heartland Dental Closes Key Transaction with Smile Design Dentistry (Sept 5, 2025)
- [4] PrivSource — Dental Acquisitions 2025
- [5] Large Practice Sales — Dental Practice Valuations Guide
- [6] Group Dentistry Now — DSO Deals September 2025
- [7] TUSK Practice Sales — Q1 2026 Dental M&A Report
- [8] VMG Health — January 2026 DSO Report (deal-velocity benchmark)
- [9] Sofer Advisors — Dental Practice Valuation: Atlanta Owners Guide 2026
- [10] Large Practice Sales — How Much Do Dental Practices Sell For?
- [11] GF Data — Year-End M&A Volume Hits Multi-Year Low (LMM size premium 2.8x, 2025)
- [12] Group Dentistry Now — DSO Mergers December 2025 (Park Dental Partners IPO)
Multiple ranges represent typical lower middle market transactions; individual deals may fall outside the band based on buyer thesis, deal structure, and seller-specific factors. This page is informational and not a formal valuation opinion.